Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman interpret the latest safety and efficacy data for JAK inhibitors in RA, including the ORAL, BEACON, BEAM, SELECT, and FINCH series in
Also included is an in-depth discussion of JAK safety, including MACE and VTE, and use in the clinic including JAK cycling
Presenters:
Stanley B. Cohen, MD
Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas
Sheetal Desai, MD, MSEd
Chief of Rheumatology
Program Director
University of California, Irvine
Irvine, California
Eric M. Ruderman, MD
Professor, Associate Chief
Division of Rheumatology
Northwestern University Feinberg School of Medicine
Clinical Practice Director
Northwestern Medical Group
Chicago, Illinois
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
Stanley B. Cohen, MD, answers questions about the ACR 2020 Pharmacologic Recommendations for the management of RA.
From ACR/ARP 2020: expert-authored commentary on evaluating RA and the utility of telemedicine, as reported by Clinical Care Options (CCO)
Safety: Frequently asked questions from the CCO Webinar series, “ A Closer Look at Evolving Treatment Strategies for Rheumatoid Arthritis”
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.